| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0044 | 0.9 |
| mRNA | BRD-K44224150 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.9 |
| mRNA | RDEA119 | FIMM | pan-cancer | AAC | -0.02 | 0.9 |
| mRNA | Fumonisin B1 | CTRPv2 | pan-cancer | AAC | 0.0047 | 0.9 |
| mRNA | BRD-K09587429 | CTRPv2 | pan-cancer | AAC | 0.0051 | 0.9 |
| mRNA | BRD-K04800985 | CTRPv2 | pan-cancer | AAC | -0.0047 | 0.9 |
| mRNA | KU 0060648 | CTRPv2 | pan-cancer | AAC | -0.0042 | 0.9 |
| mRNA | Erlotinib | FIMM | pan-cancer | AAC | 0.018 | 0.9 |
| mRNA | ELCPK | CTRPv2 | pan-cancer | AAC | -0.0059 | 0.9 |
| mRNA | Bax channel blocker | CTRPv2 | pan-cancer | AAC | -0.0039 | 0.9 |